42 Result(s)

Article

Recommendations for reporting post-transplant relapse in AML

A Rashidi, M A Linden, M-E Percival, B M Sandmaier, S Devine… in Bone Marrow Transplantation (2018)

Article

Donor and recipient plasma follistatin levels are associated with acute GvHD in Blood and Marrow Transplant Clinical Trials Network 0402

Follistatin is an angiogenic factor elevated in the circulation after allogeneic hematopoietic cell transplantation (HCT). Elevations in follistatin plasma concentrations are associated with the onset of and p...

L M Turcotte, T E DeFor, L F Newell, C S Cutler… in Bone Marrow Transplantation (2018)

Article

Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402

Epidermal growth factor (EGF) is a recently described biomarker of acute GvHD (aGvHD). Whether low plasma EGF prior to hematopoietic cell transplantation (HCT) predisposes to the development of aGvHD, or wheth...

S G Holtan, L F Newell, C Cutler, M R Verneris, T E DeFor… in Bone Marrow Transplantation (2017)

Article

Upper GI GVHD: similar outcomes to other grade II graft-versus-host disease

The significance of upper gastrointestinal tract (UGI) acute GVHD (aGVHD) compared with other grade II aGVHD is not clearly defined. We compared the outcomes of patients with grade II aGVHD with or without bio...

R S Mehta, Q Cao, S Holtan, M L MacMillan, D J Weisdorf in Bone Marrow Transplantation (2017)

Article

Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis

Allogeneic hematopoietic cell transplantation (HCT) from siblings or unrelated donors (URD) during complete remission (CR) may improve leukemia-free survival (LFS) in FMS-like tyrosine kinase 3+ (FLT3+) acute ...

C Ustun, F Giannotti, M-J Zhang, H-L Wang, C Brunstein, M Labopin, V Rocha… in Leukemia (2017)

Article

Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era

Allogeneic hematopoietic cell transplantation (alloHCT) remains a valuable treatment alternative for relapsed/refractory (R/R) Hodgkin lymphoma (HL). Data on alloHCT outcomes in the era of new HL therapies are...

L Hegerova, Q Cao, A Lazaryan, B L McClune, D J Weisdorf… in Bone Marrow Transplantation (2017)

Article

Low day +100 serum epidermal growth factor levels are associated with acute GvHD after allogeneic hematopoietic cell transplantation

F He, M R Verneris, S Cooley, B R Blazar, M L MacMillan… in Bone Marrow Transplantation (2017)

Article

Novel disease burden assessment predicts allogeneic transplantation outcomes in myelodysplastic syndrome

Among patients with myelodysplastic syndrome (MDS) undergoing hematopoietic cell transplantation (HCT), the impact of residual pretransplant cytogenetically abnormal cells on outcomes remains uncertain. We ana...

B J Trottier, Z Sachs, T E DeFor, L Shune, M Dolan… in Bone Marrow Transplantation (2016)

Article

CD56^dimCD57⁺NKG2C⁺ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT

We have recently described a specialized subset of human natural killer (NK) cells with a CD56^dimCD57⁺NKG2C⁺ phenotype that expand specifically in response to cytomegalovirus (CMV) reactivation in hematopoietic c...

F Cichocki, S Cooley, Z Davis, T E DeFor, H Schlums, B Zhang, C G Brunstein… in Leukemia (2016)

Article

Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival

Although hemorrhagic cystitis (HC) is a common complication of allogeneic hematopoietic cell transplantation (alloHCT), its risk factors and effects on survival are not well known. We evaluated HC in a large c...

L E Lunde, S Dasaraju, Q Cao, C S Cohn, M Reding, N Bejanyan… in Bone Marrow Transplantation (2015)

Article

Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome

The impact of extramedullary disease (EMD) in AML on the outcomes of allogeneic hematopoietic cell transplantation (alloHCT) is unknown. Using data from the Center for International Blood and Marrow Transplant...

S D Goyal, M-J Zhang, H-L Wang, G Akpek, E A Copelan… in Bone Marrow Transplantation (2015)

Article

Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease

The efficacy of reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT) for Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) is uncertain. We analyzed ...

V Bachanova, D I Marks, M-J Zhang, H Wang, M de Lima, M D Aljurf, M Arellano… in Leukemia (2014)

Article

Higher therapeutic CsA levels early post transplantation reduce risk of acute GVHD and improves survival

We studied whether early CsA trough levels were associated with the risk of acute GVHD in 337 patients after either sibling PBSC or double umbilical cord blood transplantation. All patients, regardless of dono...

J R Rogosheske, A D Fargen, T E DeFor, E Warlick, M Arora… in Bone Marrow Transplantation (2014)

Article

Impact of ABO-mismatch on risk of GVHD after umbilical cord blood transplantation

Recent advances in allogeneic hematopoietic cell transplant (allo-HCT) have led to an increasing use of alternative donors, including banked umbilical cord blood (UCB). Despite these advances, acute GVHD (aGVH...

R Romee, D J Weisdorf, C Brunstein, J E Wagner, Q Cao… in Bone Marrow Transplantation (2013)

Article

CXCR4 expression in CD34+ cells and unit predominance after double umbilical cord blood transplantation

P Ramirez, J E Wagner, T E DeFor, C R Eide, J S Miller, D J Weisdorf… in Leukemia (2013)

Article

Factors predicting single-unit predominance after double umbilical cord blood transplantation

Double umbilical cord blood transplantation (dUCBT), developed as a strategy to treat large number of patients with hematologic malignancies, frequently leads to the long-term establishment of a new hematopoie...

P Ramirez, J E Wagner, T E DeFor, B R Blazar, M R Verneris… in Bone Marrow Transplantation (2012)

Article

Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors

Umbilical cord blood (UCB) has increased access to hematopoietic cell transplantation (HCT) for patients without HLA-matched sibling donors (MSD). We compared outcomes of HCT using MSD (N=38) or UCB (N=60) among ...

N S Majhail, C G Brunstein, R Shanley, K Sandhu, B McClune… in Bone Marrow Transplantation (2012)

Article

Health behaviors and cancer screening practices in long-term survivors of hematopoietic cell transplantation (HCT): a report from the BMT Survivor Study

Patients undergoing hematopoietic cell transplantation (HCT) are at increased risk of chronic health conditions, including second malignant neoplasms and cardiovascular disease. Little is known about health be...

S H Armenian, C-L Sun, L Francisco, K S Baker, D J Weisdorf… in Bone Marrow Transplantation (2012)

Article

Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS

Although reduced-intensity conditioning (RIC) and non-myeloablative (NMA)-conditioning regimens have been used for over a decade, their relative efficacy vs myeloablative (MA) approaches to allogeneic hematopo...

S M Luger, O Ringdén, M-J Zhang, W S Pérez, M R Bishop… in Bone Marrow Transplantation (2012)

Article

High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation

Despite its common use in nonmyeloablative preparative regimens, the pharmacokinetics of fludarabine are poorly characterized in hematopoietic cell transplantation (HCT) recipients and exposure-response relati...

J R Long-Boyle, K G Green, C G Brunstein, Q Cao… in Bone Marrow Transplantation (2011)